Evaluation of homocystein and asymmetric dimethyl arginine levels in patients with coronary slow flow phenomenon

Basit Öğe Kaydı
dc.authorwosidBekar, Lütfü / A-6945-2019
dc.contributor.authorDemirci, Erkan
dc.contributor.authorÇelik, Oğuzhan
dc.contributor.authorKalçık, Macit
dc.contributor.authorBekar, Lütfü
dc.contributor.authorYetim, Mücahit
dc.contributor.authorDoğan, Tolga
dc.date.accessioned2021-11-01T15:02:05Z
dc.date.available2021-11-01T15:02:05Z
dc.date.issued2019
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractBackground: Previous studies have demonstrated that homocysteine and asymmetric dimethyl arginine (ADMA) levels were strongly associated with cardiovascular diseases including coronary artery disease. The aim of this study was to investigate the role of plasma homocysteine and ADMA levels in the pathogenesis of coronary slow flow (CSF) phenomenon. Methods: Twenty-three patients with CSF and 25 controls with normal coronary flow were included in this study. The quantitative measurement of coronary blood flow was performed using the thrombolysis in myocardial infarction frame count method. Plasma homocysteine and ADMA levels were determined using enzymatic assays from venous blood samples. Results: The patients with CSF had significantly higher plasma homocysteine levels than controls (16.2 +/- 7.6 vs. 12.2 +/- 2.2 mu M/L; p = 0.023). The uric acid levels were significantly higher in CSF group than controls (5.4 +/- 1.1 vs. 4.6 +/- 0.9 mg/dl; p = 0.011). Plasma ADMA levels were also higher in the CSF group; however, this was not statistically significant (0.6 +/- 0.1 vs. 0.5 +/- 0.2 mu M/L; p = 0.475). Conclusions: Increased homocysteine and uric acid levels may play an important role in the pathogenesis of CSF. Further large scale studies are required to determine the relationship between ADMA levels and CSF.
dc.identifier.citationDemirci, E., Çelik, O., Kalçık, M., Bekar, L., Yetim, M., & Doğan, T. (2019). Evaluation of homocystein and asymmetric dimethyl arginine levels in patients with coronary slow flow phenomenon. Interventional Medicine and Applied Science, 11(2), 89-94.
dc.identifier.doi10.1556/1646.11.2019.07
dc.identifier.endpage94en_US
dc.identifier.issn2061-1617
dc.identifier.issn2061-5094
dc.identifier.issue2en_US
dc.identifier.pmid32148911
dc.identifier.scopus2-s2.0-85071461643
dc.identifier.scopusqualityN/A
dc.identifier.startpage89en_US
dc.identifier.urihttps://doi.org/10.1556/1646.11.2019.07
dc.identifier.urihttps://hdl.handle.net/11491/6836
dc.identifier.volume11en_US
dc.identifier.wosWOS:000473624700003
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorBekar, Lütfü
dc.institutionauthorKalçık, Macit
dc.institutionauthorYetim, Mücahit
dc.institutionauthorDoğan, Tolga
dc.language.isoen
dc.publisherAkademiai Kiado Zrt
dc.relation.ispartofInterventional Medicine And Applied Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAsymmetric Dimethyl Arginineen_US
dc.subjectCoronary Arteryen_US
dc.subjectCoronary Slow Flowen_US
dc.subjectEndothelial Dysfunctionen_US
dc.subjectHomocysteinen_US
dc.titleEvaluation of homocystein and asymmetric dimethyl arginine levels in patients with coronary slow flow phenomenon
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
erkan-demirci2019.pdf
Boyut:
177.5 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu